Piramal Pharma Solutions

Sector: Pharma & Healthcare — CDMO/CRO Services  |  HQ: Mumbai, Maharashtra  |  Founded: 2012  |  Employees: ~7,000

Listed as: Privately held  |   |  Website →

Company overview

Piramal Pharma Solutions (PPS) is a contract development and manufacturing organization (CDMO) providing end-to-end pharmaceutical development and manufacturing services to global pharma and biotech companies. The company operates across drug substance (API) and drug product manufacturing, offering services including clinical development, commercial manufacturing, and regulatory support. It serves as a wholly-owned subsidiary of Piramal Pharma Limited, which itself is listed on the Indian stock exchanges and part of the larger Piramal Group conglomerate.

Recent developments

August 2025 - May 2026

Piramal Pharma Solutions has been aggressively expanding its antibody-drug conjugate (ADC) and bioconjugate service portfolio. The company formalized a partnership with IntoCell in late 2025 to broaden its payload-linker platform [8], followed by a collaboration with Ajinomoto Bio-Pharma Services in April 2026 to support integrated ADC development and manufacturing [6]. This strategic build-out was underscored by the unveiling of a state-of-the-art payload-linker suite at the Riverview, Michigan facility in May 2026 [2] and a new partnership with Botanix for drug substance development [1]. The Grangemouth, UK site reached a manufacturing milestone with its 1,500th ADC batch delivered in March 2026 [3].

On oral solid dosage (OSD) capabilities, Piramal introduced tablet-in-capsule technology in February 2026, expanding its drug product offerings [4][5]. The company also opened a dedicated OSD suite for NewAmsterdam Pharma in August 2025 [9] and made investments to enhance US-based OSD production capacity [10]. The Morpeth facility in the UK commemorated its 20th anniversary in March 2026 with the procurement of a Korsch X3 tablet press, signalling continued investment in advanced solid dosage manufacturing [7].

Sources (10)

1. Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development - ThePrint · ThePrint · Mon, 18 May 2026
2. Piramal Pharma Solutions unveils state-of-the-art payload-linker suite at its Riverview, Michigan facility - Manufacturing Chemist · Manufacturing Chemist · Fri, 15 May 2026
3. Piramal Pharma Solutions' Grangemouth, UK Facility Successfully Delivers 1,500th ADC Batch - PR Newswire · PR Newswire · Mon, 16 Mar 2026
4. Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities - PR Newswire · PR Newswire · Mon, 02 Feb 2026
5. Piramal Pharma Solutions introduces tablet-in-capsule capabilities - Manufacturing Chemist · Manufacturing Chemist · Wed, 04 Feb 2026
6. Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing | Corporate - EQS News · EQS News · Thu, 16 Apr 2026
7. Piramal Pharma Solutions Commemorates 20th Anniversary at Morpeth Facility with Procurement of Korsch X3 Tablet Press - PR Newswire · PR Newswire · Wed, 25 Mar 2026
8. Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its Payload-Linker Platform and Bioconjugate Capabilities - PR Newswire · PR Newswire · Thu, 30 Oct 2025
9. Piramal Pharma Solutions, NewAmsterdam Pharma open dedicated oral solid dosage form suite at Piramal... - Medical Dialogues · Medical Dialogues · Sun, 24 Aug 2025
10. Piramal Pharma Solutions makes investment to enhance oral solid dosage production capabilities in US - BioSpectrum India · BioSpectrum India · Thu, 21 Aug 2025

Financial performance and recent trajectory

Disclosed revenue (FY25): Not separately disclosed in segment-wise FY 2024-25 reporting.

Competitive position

PPS competes in the global CDMO market against players such as Lonza, Catalent, Samsung Biologics, and Thermo Fisher Scientific (Patheon), as well as Indian peers like Cipla's CDMO arm, Syngene, and Aragen. It positions itself as a cost-competitive, globally integrated CDMO with capabilities across small molecule APIs, sterile fill-finish, and biologics.

Key risks

Regulatory risk — cGMP compliance and regulatory actions from FDA, EMA, or other agencies could disrupt operations or lead to warning letters Client concentration — revenue depends on a limited number of large pharma/biotech clients, creating concentration risk if major contracts are lost or delayed Pricing pressure from cost-competitive CDMO entrants in India, China, and Eastern Europe Currency and geopolitical risk — operations across multiple geographies expose earnings to exchange rate fluctuations and cross-border trade/policy changes

Outlook

Piramal Pharma Solutions is a participant in the Indian cro / cdmo services business category, which forms part of the broader Pharma & Healthcare space. The Indian cro / cdmo services business market continues to evolve with rising organised share, premiumisation, distribution expansion, and a regulatory architecture covering the Companies Act 2013, the Income Tax Act 1961, the CGST Act 2017, the Legal Metrology Act 2009, and sectoral statutes including the Food Safety and Standards Act 2006 (for food and beverage subsegments), the Drugs and Cosmetics Act 1940 (for pharmaceutical or healthcare adjacencies), the Environment Protection Act 1986 (for emissions and effluents), and labour codes consolidated under the four 2020 labour codes. In KAMRIT's project report framework for this category, the competitive set typically includes pan-India branded leaders, multinational subsidiaries, mid-sized regional players, and a long tail of MSME participants. The structural attractiveness of the category for new entrants is a function of (a) market growth rate, (b) the share that remains with unorganised or fragmented operators, (c) the cost of regulatory compliance, and (d) the capex intensity of plant and machinery. The KAMRIT bankable DPR for this category structures a new entrant's economics against this competitive landscape. For Piramal Pharma Solutions specifically, public-domain disclosures provide a baseline view of operations, but segment-wise revenue, EBITDA, capacity utilisation, and forward capex plans are not separately broken out in many cases. Where the company is part of a listed group, the SEBI LODR and the Companies Act 2013 governance framework apply, with statutory audit conducted under SA 700 and CARO 2020 reporting. Where the company is unlisted, the Companies Act 2013 framework continues to govern with reduced public disclosure. The risk and opportunity outlook for Piramal Pharma Solutions mirrors the broader cro / cdmo services business category dynamics. Demand-side drivers include rising household consumption, urbanisation, organised retail expansion, and policy support including PLI schemes (where applicable to the segment). Supply-side risks include input cost volatility, regulatory tightening, environmental compliance escalation, and competitive intensity from larger groups or imports. Management quality, balance sheet strength, distribution depth, and the capex execution track record are the differentiators within the peer set. KAMRIT's research desk maintains a baseline reference for Piramal Pharma Solutions as a peer benchmark within the cro / cdmo services business category. For investors, lenders, or new entrant promoters seeking a fuller assessment of Piramal Pharma Solutions, KAMRIT's deep-dive company profile engagement covers financial trajectory, capacity and capex, distribution and customer concentration, regulatory exposure, and the competitive position with named peers.

KAMRIT point of view

Building or competing with Piramal?

KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the pharma & healthcare — cdmo/cro services sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of Piramal and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.

View all 1 related project report → Book a scoping call

Related KAMRIT project reports

These reports use Piramal Pharma Solutions in benchmarking and competitive analysis sections.

Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.